About NewAmsterdam Pharma
NewAmsterdam Pharma is a company based in Naarden (Netherlands) founded in 2019 by John Kastelein.. NewAmsterdam Pharma has raised $196 million across 1 funding round from investors including Kaiser Permanente, Janus Henderson Investors and Life Sciences Partners. The company has 68 employees as of December 31, 2024. NewAmsterdam Pharma offers products and services including Obicetrapib. NewAmsterdam Pharma operates in a competitive market with competitors including Tenaya Therapeutics, Cellino, Enliven Therapeutics, Nuvalent and Arrakis Therapeutics, among others.
- Headquarter Naarden, Netherlands
- Employees 68 as on 31 Dec, 2024
- Founders John Kastelein
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Newamsterdam Pharma Company N.V.
-
Annual Revenue
$45.56 M223.37as on Dec 31, 2024
-
Net Profit
$-241.6 M-36.54as on Dec 31, 2024
-
EBITDA
$-176.18 M2.53as on Dec 31, 2024
-
Total Equity Funding
$196 M (USD)
in 1 rounds
-
Latest Funding Round
$196 M (USD), Series A
Jan 14, 2021
-
Investors
Kaiser Permanente
& 8 more
-
Employee Count
68
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of NewAmsterdam Pharma
NewAmsterdam Pharma is a publicly listed company on the NASDAQ with ticker symbol NAMS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of NewAmsterdam Pharma
NewAmsterdam Pharma offers a comprehensive portfolio of products and services, including Obicetrapib. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Investigational CETP inhibitor to lower LDL-C and reduce cardiovascular risk.
Unlock access to complete
Unlock access to complete
Funding Insights of NewAmsterdam Pharma
NewAmsterdam Pharma has successfully raised a total of $196M through 1 strategic funding round. The most recent funding activity was a Series A round of $196 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $196.0M
-
First Round
First Round
(14 Jan 2021)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2021 | Amount | Series A - NewAmsterdam Pharma | Valuation | Morningside , Forbion |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in NewAmsterdam Pharma
NewAmsterdam Pharma has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Kaiser Permanente, Janus Henderson Investors and Life Sciences Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are invested in by Morningside, a VC fund.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on lifescience and healthcare sectors
|
Founded Year | Domain | Location | |
|
US private equity investments are managed by BVF Partners.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by NewAmsterdam Pharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - NewAmsterdam Pharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Newamsterdam Pharma Comparisons
Competitors of NewAmsterdam Pharma
NewAmsterdam Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tenaya Therapeutics, Cellino, Enliven Therapeutics, Nuvalent and Arrakis Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| domain | founded_year | HQ Location |
Developer of autologous cell therapies
|
|
| domain | founded_year | HQ Location |
Developer of drugs for solid tumours and blood cancers
|
|
| domain | founded_year | HQ Location |
Therapeutic solutions for cancer, including NSCLC inhibitors, are developed.
|
|
| domain | founded_year | HQ Location |
Provider of tools for the analysis of RNA structures
|
|
| domain | founded_year | HQ Location |
Specialized drugs are developed for genetic heart diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Newamsterdam Pharma
Frequently Asked Questions about NewAmsterdam Pharma
When was NewAmsterdam Pharma founded?
NewAmsterdam Pharma was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Where is NewAmsterdam Pharma located?
NewAmsterdam Pharma is headquartered in Naarden, Netherlands. It is registered at Naarden, North Holland, Netherlands.
Who is the current CEO of NewAmsterdam Pharma?
Michael Davidson is the current CEO of NewAmsterdam Pharma.
Is NewAmsterdam Pharma a funded company?
NewAmsterdam Pharma is a funded company, having raised a total of $196M across 1 funding round to date. The company's 1st funding round was a Series A of $196M, raised on Jan 14, 2021.
How many employees does NewAmsterdam Pharma have?
As of Dec 31, 2024, the latest employee count at NewAmsterdam Pharma is 68.
What is the annual revenue of NewAmsterdam Pharma?
Annual revenue of NewAmsterdam Pharma is $45.56M as on Dec 31, 2024.
What does NewAmsterdam Pharma do?
NewAmsterdam Pharma was founded in 2019 and is based in Naarden, Netherlands. Focus is placed on the pharmaceutical sector, where small molecule therapies for cardio-metabolic and cardio-renal diseases are developed. Obicetrapib, an oral cholesterol ester transfer protein inhibitor, is advanced to target Apolipoprotein B and low-density lipoprotein cholesterol levels. Operations involve clinical development of these treatments for related metabolic conditions.
Who are the top competitors of NewAmsterdam Pharma?
NewAmsterdam Pharma's top competitors include Esperion Therapeutics, Tenaya Therapeutics and Nuvalent.
What products or services does NewAmsterdam Pharma offer?
NewAmsterdam Pharma offers Obicetrapib.
Is NewAmsterdam Pharma publicly traded?
Yes, NewAmsterdam Pharma is publicly traded on NASDAQ under the ticker symbol NAMS.
Who are NewAmsterdam Pharma's investors?
NewAmsterdam Pharma has 9 investors. Key investors include Kaiser Permanente, Janus Henderson Investors, Life Sciences Partners, Medpace, and Morningside.
What is NewAmsterdam Pharma's ticker symbol?
The ticker symbol of NewAmsterdam Pharma is NAMS on NASDAQ.